** Shares of Amplia Therapeutics Ltd ATX.AX fall as much as 8.8% to A$0.26, their worst session since Nov 19, 2020
** The drug developer plans sales of 16.59 mln new shares to new and existing institutional investors, raising A$3.8 mln ($2.94 mln) to fund clinical trials in pancreatic cancer and pulmonary fibrosis Says the new shares will be issued at A$0.23 apiece, representing 10% discount to the 15-day volume weighted price of shares traded up to April 29
** The main stock index S&P/ASX 200 .AXJO climbs 0.4%
** As of last close, stock up 18.% this year
($1 = 1.2923 Australian dollars) (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)